Los Angeles Capital Management
NRIX icon

Los Angeles Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Los Angeles Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.11K Hold
394
– – ﹤0.01% 2075
2025
Q4 		$5.04K Buy
+394
New +$5.66K ﹤0.01% 2280
2024
Q4 		– Sell
-26,544
Closed -$596K – 1202
2024
Q3 		$596K Sell
26,544
-6,701
-20% -$152K ﹤0.01% 812
2024
Q2 		$694K Sell
33,245
-69,076
-68% -$1.08M ﹤0.01% 766
2024
Q1 		$1.5M Sell
102,321
-23,680
-19% -$255K 0.01% 565
2023
Q4 		$1.3M Buy
126,001
+162
+0.1% +$1.11K ﹤0.01% 590
2023
Q3 		$989K Buy
125,839
+16,989
+16% +$155K ﹤0.01% 645
2023
Q2 		$1.09M Buy
108,850
+5,071
+5% +$51.7K ﹤0.01% 634
2023
Q1 		$922K Sell
103,779
-2,700
-3% -$28.1K ﹤0.01% 696
2022
Q4 		$1.17M Buy
106,479
+38,824
+57% +$468K 0.01% 658
2022
Q3 		$882K Buy
67,655
+54,390
+410% +$861K ﹤0.01% 746
2022
Q2 		$168K Buy
13,265
+260
+2% +$2.95K ﹤0.01% 1276
2022
Q1 		$182K Hold
13,005
– – ﹤0.01% 1366
2021
Q4 		$376K Buy
+13,005
New +$394K ﹤0.01% 1144

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Los Angeles Capital Management's NRIX Position: Q1 2026 in Review

Los Angeles Capital Management held its Nurix Therapeutics (NRIX) position steady in Q1 2026 at 394 shares worth $6.11K. The position accounts for ﹤0.01% of the portfolio, ranked #2075.

Los Angeles Capital Management first reported a position in NRIX in Q4 2021 and has held it in 14 quarters since. The position peaked at $1.5M in Q1 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Los Angeles Capital Management held 394 shares of Nurix Therapeutics worth $6.11K as of Q1 2026.
  • Los Angeles Capital Management left its Nurix Therapeutics share count unchanged in Q1 2026.
  • Nurix Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #2075 holding.
  • Los Angeles Capital Management first reported a position in Nurix Therapeutics in Q4 2021 and has held it in 14 quarters since.
  • Los Angeles Capital Management's Nurix Therapeutics position peaked at $1.5M in Q1 2024.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.